Timothy D Mchugh

List of Publications by Year
in descending order

89 papers	9,932 citations	66343 42 h-index	51608 86 g-index
90 all docs	90 docs citations	90 times ranked	13506 citing authors

#	Article	IF	Citations
1	Pre-Clinical Tools for Predicting Drug Efficacy in Treatment of Tuberculosis. Microorganisms, 2022, 10, 514.	3.6	3
2	Culture-Free Enumeration of Mycobacterium tuberculosis in Mouse Tissues Using the Molecular Bacterial Load Assay for Preclinical Drug Development. Microorganisms, 2022, 10, 460.	3.6	3
3	Ancient and recent differences in the intrinsic susceptibility of Mycobacterium tuberculosis complex to pretomanid. Journal of Antimicrobial Chemotherapy, 2022, 77, 1685-1693.	3.0	34
4	TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase IIâ€“III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis. Trials, 2022, 23, .	1.6	22
5	Reducing the risk of tuberculosis transmission for HCWs in high incidence settings. Antimicrobial Resistance and Infection Control, 2021, 10, 106.	4.1	12
6	Profiling and identification of novel rpoB mutations in rifampicin-resistant Mycobacterium tuberculosis clinical isolates from Pakistan. Journal of Infection and Chemotherapy, 2021, 27, 1578-1583.	1.7	2
7	Rifamycins: do not throw the baby out with the bathwater. Is rifampicin still an effective anti-tuberculosis drug?. Future Medicinal Chemistry, 2021, 13, 2129-2131.	2.3	2
8	Improving the Drug Development Pipeline for Mycobacteria: Modelling Antibiotic Exposure in the Hollow Fibre Infection Model. Antibiotics, 2021, 10, 1515.	3.7	8
9	Improving the Potency of N-Aryl-2,5-dimethylpyrroles against Multidrug-Resistant and Intracellular Mycobacteria. ACS Medicinal Chemistry Letters, 2020, 11, 638-644.	2.8	9
10	COVID-19â€”Zoonosis or Emerging Infectious Disease?. Frontiers in Public Health, 2020, 8, 596944.	2.7	104
11	Enrichment of the airway microbiome in people living with HIV with potential pathogenic bacteria despite antiretroviral therapy. EClinicalMedicine, 2020, 24, 100427.	7.1	4
12	Carprofen elicits pleiotropic mechanisms of bactericidal action with the potential to reverse antimicrobial drug resistance in tuberculosis. Journal of Antimicrobial Chemotherapy, 2020, 75, 3194-3201.	3.0	16
13	Li Wenliang, a face to the frontline healthcare worker. The first doctor to notify the emergence of the SARS-CoV-2, (COVID-19), outbreak. International Journal of Infectious Diseases, 2020, 93, 205-207.	3.3	49
14	Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. New England Journal of Medicine, 2020, 382, 893-902.	27.0	554
15	Is Africa prepared for tackling the COVID-19 (SARS-CoV-2) epidemic. Lessons from past outbreaks, ongoing pan-African public health efforts, and implications for the future. International Journal of Infectious Diseases, 2020, 93, 233-236.	3.3	150
16	The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health â€” The latest 2019 novel coronavirus outbreak in Wuhan, China. International Journal of Infectious Diseases, 2020, 91, 264-266.	3.3	2,658
17	Validation of Differentially Expressed Immune Biomarkers in Latent and Active Tuberculosis by Real-Time PCR. Frontiers in Immunology, 2020, 11, 612564.	4.8	16
18	Management and control of tuberculosis control in socially complex groups: a research programme including three RCTs. Programme Grants for Applied Research, 2020, 8, 1-76.	1.0	3

#	Article	IF	Citations
19	Fluoroquinolones and isoniazid-resistant tuberculosis: implications for the 2018 WHO guidance. European Respiratory Journal, 2019, 54, 1900982.	6.7	14
20	A Systematic Review and Meta-analysis of the Diagnostic Accuracy of Nucleic Acid Amplification Tests for Tuberculous Meningitis. Journal of Clinical Microbiology, 2019, 57, .	3.9	50
21	Smartphone-enabled video-observed versus directly observed treatment for tuberculosis: a multicentre, analyst-blinded, randomised, controlled superiority trial. Lancet, The, 2019, 393, 1216-1224.	13.7	156
22	New drugs to treat difficult tuberculous and nontuberculous mycobacterial pulmonary disease. Current Opinion in Pulmonary Medicine, 2019, 25, 271-280.	2.6	21
23	Airway microbiome in adult survivors of extremely preterm birth: the EPICure study. European Respiratory Journal, 2019, 53, 1801225.	6.7	20
24	Monkeypox â€" Enhancing public health preparedness for an emerging lethal human zoonotic epidemic threat in the wake of the smallpox post-eradication era. International Journal of Infectious Diseases, 2019, 78, 78-84.	3.3	133
25	Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study. BMC Medicine, 2018, 16, 46.	5.5	46
26	Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies. Lancet Infectious Diseases, The, 2018, 18, e183-e198.	9.1	281
27	Tuberculosis: advances and challenges in development of new diagnostics and biomarkers. Lancet Infectious Diseases, The, 2018, 18, e199-e210.	9.1	244
28	Direct Whole-Genome Sequencing of Sputum Accurately Identifies Drug-Resistant Mycobacterium tuberculosis Faster than MGIT Culture Sequencing. Journal of Clinical Microbiology, 2018, 56, .	3.9	131
29	Toxicity associated with tuberculosis chemotherapy in the REMoxTB study. BMC Infectious Diseases, 2018, 18, 317.	2.9	16
30	Use of whole-genome sequencing to distinguish relapse from reinfection in a completed tuberculosis clinical trial. BMC Medicine, 2017, 15, 71.	5.5	57
31	Assessment of treatment response by colony forming units, time to culture positivity and the molecular bacterial load assay compared in a mouse tuberculosis model. Tuberculosis, 2017, 105, 113-118.	1.9	16
32	Rapid identification of a Mycobacterium tuberculosis full genetic drug resistance profile through whole genome sequencing directly from sputum. International Journal of Infectious Diseases, 2017, 62, 44-46.	3.3	40
33	Blood and sputum eosinophils in COPD; relationship with bacterial load. Respiratory Research, 2017, 18, 88.	3.6	94
34	Pediatric tuberculosis-human immunodeficiency virus co-infection in the United Kingdom highlights the need for better therapy monitoring tools: a case report. Journal of Medical Case Reports, 2017, 11, 52.	0.8	4
35	Spot sputum samples are at least as good as early morning samples for identifying Mycobacterium tuberculosis. BMC Medicine, 2017, 15, 192.	5.5	12
36	A comparison of liquid and solid culture for determining relapse and durable cure in phase III TB trials for new regimens. BMC Medicine, 2017, 15, 207.	5.5	12

#	Article	IF	Citations
37	Genetic variation in Mycobacterium tuberculosis isolates from a London outbreak associated with isoniazid resistance. BMC Medicine, 2016, 14, 117.	5.5	16
38	Repurposing drugs for treatment of tuberculosis: a role for non-steroidal anti-inflammatory drugs. British Medical Bulletin, 2016, 118, 138-148.	6.9	63
39	The use of digital PCR to improve the application of quantitative molecular diagnostic methods for tuberculosis. BMC Infectious Diseases, 2016, 16, 366.	2.9	41
40	World TB Day 2016: an interview with leading experts in tuberculosis research. BMC Medicine, 2016, 14, 55.	5.5	2
41	Uniting to end the TB epidemic: advances in disease control from prevention to better diagnosis and treatment. BMC Medicine, 2016, 14, 47.	5.5	10
42	Profiling persistent tubercule bacilli from patient sputa during therapy predicts early drug efficacy. BMC Medicine, 2016, 14, 68.	5.5	55
43	The transmission of Mycobacterium tuberculosis in high burden settings. Lancet Infectious Diseases, The, 2016, 16, 227-238.	9.1	149
44	Design and Synthesis of 1-((1,5-Bis(4-chlorophenyl)-2-methyl-1H-pyrrol-3-yl)methyl)-4-methylpiperazine (BM212) and N-Adamantan-2-yl-Nâ€²-((E)-3,7-dimethylocta-2,6-dienyl)ethane-1,2-diamine (SQ109) Pyrrole Hybrid Derivatives: Discovery of Potent Antitubercular Agents Effective against Multidrug-Resistant Mycobacteria. Journal of Medicinal Chemistry, 2016, 59, 2780-2793.	6.4	51
45	Mycobacterium tuberculosis Is Resistant to Isoniazid at a Slow Growth Rate by Single Nucleotide Polymorphisms in katG Codon Ser315. PLoS ONE, 2015, 10, e0138253.	2.5	29
46	Rapid Whole-Genome Sequencing of Mycobacterium tuberculosis Isolates Directly from Clinical Samples. Journal of Clinical Microbiology, 2015, 53, 2230-2237.	3.9	242
47	Commemorating World Tuberculosis Day 2015. International Journal of Infectious Diseases, 2015, 32, 1-4.	3.3	2
48	Airway bacteria and respiratory symptoms are common in ambulatory HIV-positive UK adults. European Respiratory Journal, 2015, 46, 1208-1211.	6.7	8
49	Highly Reproducible Absolute Quantification of Mycobacterium tuberculosis Complex by Digital PCR. Analytical Chemistry, 2015, 87, 3706-3713.	6.5	87
50	Genomic Investigations Unmask Mycoplasma amphoriforme, a New Respiratory Pathogen. Clinical Infectious Diseases, 2015, 60, 381-388.	5.8	10
51	A Dose-Ranging Trial to Optimize the Dose of Rifampin in the Treatment of Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 1058-1065.	5.6	260
52	Improving the Tuberculosis Drug Development Pipeline. Chemical Biology and Drug Design, 2015, 86, 951-960.	3.2	20
53	Towards host-directed therapies for tuberculosis. Nature Reviews Drug Discovery, 2015, 14, 511-512.	46.4	110
54	Effects of different antibiotic classes on airway bacteria in stable COPD using culture and molecular techniques: a randomised controlled trial. Thorax, 2015, 70, 930-938.	5.6	61

#	Article	IF	Citations
55	A Step toward an Optimized Rifampin Dose Completed. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 525-526.	5.6	7
56	Standardization of Nucleic Acid Tests for Clinical Measurements of Bacteria and Viruses. Journal of Clinical Microbiology, 2015, 53, 2008-2014.	3.9	36
57	Evaluation of a Short, On-Plate Formic Acid Extraction Method for Matrix-Assisted Laser Desorption Ionizationâ€"Time of Flight Mass Spectrometry-Based Identification of Clinically Relevant Yeast Isolates. Journal of Clinical Microbiology, 2014, 52, 1253-1255.	3.9	15
58	New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects. Lancet Infectious Diseases, The, 2014, 14, 327-340.	9.1	302
59	High-Dose Rifapentine with Moxifloxacin for Pulmonary Tuberculosis. New England Journal of Medicine, 2014, 371, 1599-1608.	27.0	383
60	2-Hydroxy-substituted cinnamic acids and acetanilides are selective growth inhibitors of Mycobacterium tuberculosis. MedChemComm, 2014, 5, 47-50.	3.4	43
61	World TB Day 2014: Reach the three million: a TB test, treatment and cure for all. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2014, 108, 119-120.	1.8	0
62	Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis. New England Journal of Medicine, 2014, 371, 1577-1587.	27.0	551
63	The Molecular Bacterial Load Assay Replaces Solid Culture for Measuring Early Bactericidal Response to Antituberculosis Treatment. Journal of Clinical Microbiology, 2014, 52, 3064-3067.	3.9	62
64	Whole-genome sequencing to establish relapse or re-infection with Mycobacterium tuberculosis: a retrospective observational study. Lancet Respiratory Medicine,the, 2013, 1, 786-792.	10.7	184
65	Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment. Lancet Respiratory Medicine,the, 2013, 1, 462-470.	10.7	151
66	Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infectious Diseases, The, 2013, 13, 529-539.	9.1	243
67	Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. Lancet Infectious Diseases, The, 2013, 13, 349-361.	9.1	385
68	Antitubercular specific activity of ibuprofen and the other 2-arylpropanoic acids using the HT-SPOTi whole-cell phenotypic assay. BMJ Open, 2013, 3, e002672.	1.9	74
69	Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD. Thorax, 2012, 67, 1075-1080.	5.6	193
70	Tuberculosis Diagnostics and Biomarkers: Needs, Challenges, Recent Advances, and Opportunities. Journal of Infectious Diseases, 2012, 205, S147-S158.	4.0	154
71	Detection and identification of bacteria in clinical samples by 16S rRNA gene sequencing: comparison of two different approaches in clinical practice. Journal of Medical Microbiology, 2012, 61, 483-488.	1.8	78
72	An antibacterial from Hypericum acmosepalum inhibits ATP-dependent MurE ligase from Mycobacterium tuberculosis. International Journal of Antimicrobial Agents, 2012, 39, 124-129.	2.5	52

#	Article	IF	Citations
73	Drug-Resistant Tuberculosisâ€"Current Dilemmas, Unanswered Questions, Challenges, and Priority Needs. Journal of Infectious Diseases, 2012, 205, S228-S240.	4.0	140
74	Strategies and Challenges Involved in the Discovery of New Chemical Entities During Early-Stage Tuberculosis Drug Discovery. Journal of Infectious Diseases, 2012, 205, S258-S264.	4.0	15
75	Molecular Bacterial Load Assay, a Culture-Free Biomarker for Rapid and Accurate Quantification of Sputum Mycobacterium tuberculosis Bacillary Load during Treatment. Journal of Clinical Microbiology, 2011, 49, 3905-3911.	3.9	97
76	Methods to Determine Fitness in Bacteria. Methods in Molecular Biology, 2010, 642, 113-121.	0.9	37
77	Enhanced heterogeneity of rpoB in Mycobacterium tuberculosis found at low pH. Journal of Antimicrobial Chemotherapy, 2009, 63, 1118-1120.	3.0	16
78	Identification of 2-Aminothiazole-4-Carboxylate Derivatives Active against Mycobacterium tuberculosis H37Rv and the Î²-Ketoacyl-ACP Synthase mtFabH. PLoS ONE, 2009, 4, e5617.	2.5	47
79	A Practical Guide to Measuring Mutation Rates in Antibiotic Resistance. Antimicrobial Agents and Chemotherapy, 2008, 52, 1209-1214.	3.2	66
80	Biomarkers of treatment response in clinical trials of novel antituberculosis agents. Lancet Infectious Diseases, The, 2007, 7, 481-490.	9.1	65
81	Direct detection of heteroresistance in Mycobacterium tuberculosis using molecular techniques. Journal of Medical Microbiology, 2006, 55, 1157-1158.	1.8	10
82	Origins and properties of Mycobacterium tuberculosis isolates in London. Journal of Medical Microbiology, 2005, 54, 575-582.	1.8	27
83	Early bactericidal activity of a moxifloxacin and isoniazid combination in smear-positive pulmonary tuberculosis. Journal of Antimicrobial Chemotherapy, 2005, 56, 1169-1171.	3.0	34
84	Analysis of rpoB and pncA mutations in the published literature: an insight into the role of oxidative stress in Mycobacterium tuberculosis evolution?. Journal of Antimicrobial Chemotherapy, 2005, 55, 674-679.	3.0	54
85	Effect of subinhibitory concentrations of ciprofloxacin on Mycobacterium fortuitum mutation rates. Journal of Antimicrobial Chemotherapy, 2005, 56, 344-348.	3.0	96
86	Tuberculosis: amplification-based clinical diagnostic techniques. International Journal of Biochemistry and Cell Biology, 2003, 35, 1407-1412.	2.8	33
87	Multiple Drug-ResistantMycobacterium tuberculosis:Evidence for Changing Fitness Following Passage Through Human Hosts. Microbial Drug Resistance, 2002, 8, 273-279.	2.0	35
88	Application of SSCP to Identification of Resistance Mutations. , 2001, 48, 31-37.		1
89	The biological cost of antimicrobial resistance. Trends in Microbiology, 1997, 5, 337-339.	7.7	32